Updated on 15 October 2013
Stehlin Foundation partners with NMT to develop formulated CZ48 drug using its proprietary High Gravity Controlled Precipitation (HGCP) Technology
Singapore: NanoMaterials Technology (NMT), a Singapore based company, has signed an exclusive material supply agreement with Houston-based CHRISTUS Stehlin Foundation for Cancer Research (Stehlin Foundation) on a formulated CZ48 drug for a Phase I clinical (human) trial.
CZ48 is an analog synthesized by the Stehlin Foundation from Camptothecin, an alkaloid extracted from the Chinese tree camptotheca acuminata. When Camptothecin and many of its derivatives are used in humans, the enzymes inactivate some of the drug molecules, eliminating their anti-cancer effect. However, CZ48 is a stable form of Camptothecin, and resistant to inactivation while circulating in the human bloodstream. This topoisomerase I inhibitor has very low toxicity even at more than 20 times the therapeutic dose, and eradicated 29 different human cancers transplanted into the Stehlin Foundation's athymic nude mice in pre-clinical studies.
Stehlin Foundation has partnered with NMT to develop the formulated CZ48 drug using its proprietary High Gravity Controlled Precipitation (HGCP) Technology to elevate absorption by decreasing the size of the CZ48 drug particle. Pre-clinical studies have indicated that a significantly lower dosage with only 25 percent of the original CZ48 molecule is required to achieve complete tumor inhibition using the formulated CZ48 drug.
Under the terms of the agreement, NMT will provide the formulated CZ48 capsules to the Stehlin Foundation for the Phase I study.
"We anticipate launching the Phase I clinical trial with the new formulation of CZ48 during the first quarter of 2014. The study should involve around 30 patients and require 24 months for completion," said Mr. Robert Anderson, President, Stehlin Foundation. "If Phase I results are as expected, we will move into Phase II."